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'llions of postmenopausal women in the United States at risk for both osteoporosis and breast cancer. Both of these diseases cause thousands of deaths each year. Selective estrogen receptor modulators (SERMs) may offer a preventive strategy. SERMs. including torernifene, raloxifene, and tarnoxifen, are competitive inhibitors of estrogen binding to estrogen receptors (ERs). These SERMs can have mixed agonist and antagonist activity. depending on the target tissue (Conzen, Ellis. & Hayes. 2010) . Raloxifene and tarnoxifen have antiestrogenic activity in breast tissue. thereby reducing epithelial cell proliferation (Chen. 2010) . SERMs also provide some protection against menopausal bone loss, presumably due to their partial agonist activity (Conzen et al.• 2010) .
Despite evidence that chemoprevention of breast cancer is effective, it is an underutilized strategy (Vogel.2010) . Although first-and second-generation SERMs tarnoxifen and raloxifene are approved for prevention of breast cancer in high-risk women. neither agent has been widely used in the United States for this indication.
It has been posited that the broad use of SERMs in chemoprevention of breast cancer has not been adopted for several reasons. including their contraindication with concurrent hormone E-mail: schalupk@hsph.harvarri .edu. doi:10.3928108910162-20101228-04 replacement therapy. Despite the results of the Women's Health Initiative. hormone replacement therapy is still extremely common among postmenopausal women. Additionally. many women mistakenly believe that their potential for SERM therapy-related side effects is greater than their risk of breast cancer. Finally, women frequently overestimate the risk of endometrial cancer with tarnoxifen use, or are not aware that raloxifene use does not present any increased risk of uterine malignancy (Vogel. 2010) .
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Lasofoxifene, a third-generation SERM. appears to represent a significant advance in the chemoprophylaxis of breast cancer, In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial. postmenopausal women (n = 8,556) 59 to 80 years old with low bone density and normal mammograms were randomly assigned to one of two doses of lasofoxifene (0.25 and 0.5 mg) or placebo. Researchers examined the incidence of nonvertebral fractures and ER-positive breast cancer at 5 years (LaCroix et al., 2010) .
Lasofoxifene (O.5-mg dose) significantly lowered the incidence of all breast cancers (including noninvasive ductal carcinoma in situ) by 79% and invasive ER-positive tumors by 83% when compared with placebo. Nested case-control analysis of 49 incident breast cancer case patients and 156 randomly selected unaffected control subjects from the PEARL trial showed that women with baseline estradiol levels below the median value (0.35 ng/dl) were substantially less likely to be diagnosed with breast cancer (including invasive ER-positive tumors) than were women with higher estradiol levels. Among women with higher levels of estradiol. lasofoxifene was associated with a significant 89% reduction in overall breast cancer risk, whereas breast cancer risk reduction did not achieve statistical significance in women with lower estradiol levels (LaCroix et al.. 2010) .
Statistically significant reductions in the incidence of vertebral fractures (42%). nonvertebral fractures (24%), and ER-positive breast cancer (81%), including invasive and noninvasive. were observed with the 0.5-mg dose of lasofoxifene when compared with placebo. Additionally. statistically significant reductions in major coronary events (32%) and stroke (36%) were observed with 0.5 mg of lasofoxifene compared with placebo. These effects have not been observed in previous trials with tamoxifen or raloxifene (LaCroix et aI..2010).
More complete information about the long-term effects of lasofoxifene is necessary. However, lasofoxifene appears to hold promise in chernoprevention of both breast cancer and osteoporotic fractures in postmenopausal women.
